Dec 20, 2022 · This is the sixteenth patient dosed with IMX-110 to-date, and the second patient dosed so far in December 2022. This patient has a relapsed/refractory pecoma, a rare form of soft tissue sarcoma, a connective tissue cancer.

Sep 30, 2021 · IMX-110 is a Tissue-Specific Therapeutic TM built on ImmixBio's TME Normalization TM Technology encapsulating a poly-kinase inhibitor and apoptosis inducer delivered deep into the tumor...

May 3, 2023 · The novel approach combining TSTx IMX-110 with anti-PD-1 antibody tislelizumab is designed to expand the population of cancer patients experiencing extended remissions from immunotherapies by converting immunologically “cold” tumors “hot”.

Jan 25, 2022 · IMX-110 + anti-PD-1 produced 63-day median survival in a genetic (KPC) pancreatic cancer mouse model in which mice develop their own pancreatic cancer and have an intact immune system

Jan 19, 2022 · Our lead asset IMX-110, currently in Phase 1b/2a clinical trials, holds orphan drug designation (ODD) by the FDA for soft tissue sarcoma, and has received Rare Pediatric Disease Designation...

May 3, 2023 · Immex Biopharma announces dosing of first 2 patients in its IMX-110 + BeiGene/Novartis anti-PD-1 tislelizumab phase 1b/2a combination clinical trial in patients with advanced cancer.

May 4, 2023 · Immix Biopharma has reported early positive interim data from its ongoing Phase Ib/IIa dose escalation clinical trial IMMINENT-01 of IMX-110 for the treatment of advanced metastatic colorectal cancer.

May 5, 2023 · Immix Biopharma announces early positive IMX-110 interim clinical trial data demonstrating 100% tumor shrinkage in advanced metastatic colorectal cancer at the lowest dose of IMX-110 + BeiGene / Novartis anti-PD-1 antibody tislelizumab.

Imx-110 is a first-in-class combination therapy designed to inhibit cancer resistance and evolvability while inducing apoptosis. Imx-110 contains NF-kB/Stat3/pan-kinase inhibitor curcumin combined with a small amount of doxorubicin encased in a nano-sized delivery system for optimal tumor penetration.

May 3, 2023 · IMMINENT-01 is a first-of-its-kind, ongoing phase 1b/2a clinical trial combining tissue specific therapeutic IMX-110 with BeiGene / Novartis’ anti-PD-1 antibody tislelizumab, in patients with...